Dr. Ayal Aizer

Dr. Ayal Aizer is a radiation oncologist in Boston, MA at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.

Dr. Aizer is an Assistant Professor of Radiation Oncology at Harvard Medical School who serves as the Director of Central Nervous System Radiation Oncology at Brigham and Women’s Hospital / Dana-Farber Cancer Institute in Boston, MA.

He completed medical school at Yale School of Medicine in 2009 before pursuing radiation oncology residency at the Harvard Radiation Oncology Program, which he completed in 2014. Dr. Aizer specializes in the management of brain metastases and his research efforts seek to improve outcomes in this population. He leads several prospective clinical trials involving patients with brain metastases and has published both retrospective and large data-based studies centered on the management of patients with this condition.

Dr. Peter Fecci

Dr. Peter Fecci is a neurosurgeon and Director of the Center for Brain & Spine Metastasis at Duke University. He performs surgeries to treat brain tumors including the emerging technique called LITT or laser interstitial thermal therapy. He is also a cancer researcher and serves as the Director of the Brain Tumor Immunotherapy Program also at Duke.

Peter Fecci, MD PhD, is currently an Associate Professor of Neurosurgery, Pathology, Immunology, and Biomedical Engineering at Duke University, where he also serves as the Director for the Duke Center for Brain and Spine Metastasis, as well as for the Duke Brain Tumor Immunotherapy Program.

A neurosurgeon-scientist, Dr. Fecci focuses clinically on intrinsic brain tumors, both primary and metastatic. In the research realm, he heads an NIH-funded laboratory that focuses on integrating strategies for reversing cancer-induced T cell dysfunction with current immune-based platforms. For his research contributions, he was a recent recipient of the Cancer Research Institute Lloyd J. Old STAR Award and was likewise inducted into the American Society for Clinical Investigation.

Dr. Fecci also serves as multi-PI for the Duke R25 training grant. His recent work on brain tumor-induced T cell sequestration and exhaustion has produced numerous high profile publications. He is now actively engaged in exploring novel drug targets and therapeutics that his group has uncovered for side-stepping brain tumor-imposed immune dysfunction and for newly licensing immune-based approaches in this patient population.


Dr. Priya Kumthekar

Dr. Priya Kumthekar is a neuro-oncologist from Northwestern University who treats primary brain tumors, but has a specific interest in metastatic disease to the brain from cancers like breast cancer. She leads multiple clinical trials to advance the field of neuro-oncology to improve care for patients.

Dr. Kumthekar is a UCNS certified neuro-oncologist from Northwestern University dedicated to patient and care and moving the field of brain tumor forward primarily through her leadership on clinical trials.

She is currently involved in and leads many clinical trials including being the overall principal investigator of five investigator initiated treatment trials as well as the site principal investigator (PI) of over a dozen additional collaborative brain tumor treatment trials. Dr. Kumthekar is the planned study chair/overall PI for a multicenter, international breast cancer leptomeningeal clinical trial scheduled to open in Q4 2020.

Dr. Kumthekar has also been actively involved in the NCI funded clinical trials for many years. Within the NCTN (National Clinical Trials Network) and serves in leadership roles, particularly with the Alliance for Clinical Trials (Alliance”) for several years.

In 2016, Dr. Kumthekar was appointed as the national Executive Officer of Neuro-Oncology at the Alliance. In this role, she oversees the conception and development of clinical trials in these two areas from early phase through registration studies. Dr. Kumthekar has teamed with various scientists both at Northwestern and at other institutions with the goal of using translational research to advance the field. These partnerships allow for cutting edge scientific discoveries to be successfully brought to the clinic for brain tumor patients to benefit.



Dr. Nancy Lin

Dr. Nancy Lin is a medical oncologist in Boston, MA at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She specializes in the care of patients with all stages of breast cancer. Her research focuses upon improving the outcomes of people living with metastatic breast cancer, including a particular focus on the challenge of breast cancer brain metastases. She has led multiple clinical trials which have led to new treatment options for patients with breast cancer that has metastasized to the brain.

Dr. Nancy Lin is a medical oncologist at Dana-Farber Cancer Institute (DFCI) and Associate Professor of Medicine at Harvard Medical School.

Dr. Lin received her medical degree at Harvard Medical School and subsequently completed her residency in Internal Medicine at Brigham & Women’s Hospital and a fellowship in Hematology/Oncology at Dana-Farber/Partners Cancer Care. Since 2018, she has served as Associate Chief of the Division of Breast Oncology at DFCI. Dr. Lin’s focus is on developing novel targeted therapies for patients with advanced breast cancer and exploring mechanisms of drug resistance, with a particular interest in patients with breast cancer that has metastasized to the brain.

Dr. Lin is leading multiple ongoing and planned clinical trials evaluating a variety of targeted approaches in patients with metastatic breast cancer. Her work is highly collaborative and involves close working relationships with clinicians, laboratory investigators, and patient advocates. Dr. Lin’s honors and awards include a Young Investigator Award and Career Development Award from the American Society of Clinical Oncology. She is a member of the Massachusetts Medical Society, American Society of Clinical Oncology, Alliance for Clinical Trials in Oncology, and Translational Breast Cancer Research Consortium.